AGP
ORKA

Artia Global Partners’s Oruka Therapeutics ORKA Stock Holding History

Artia Global Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,380
Closed -$75.7K – 48
2025
Q1 		$75.7K Buy
+7,380
New +$92K 0.02% 35

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artia Global Partners's ORKA Position: Q2 2025 in Review

Artia Global Partners sold out of Oruka Therapeutics (ORKA) in Q2 2025, closing a stake of 7,380 shares — an estimated $75.7K sold.

Artia Global Partners first reported a position in ORKA in Q1 2025 and held it in 1 quarter. The position peaked at $75.7K in Q1 2025. 81 funds tracked by Wall St. Rank hold ORKA as of Q2 2025.

  • Artia Global Partners reported no remaining Oruka Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Artia Global Partners sold 7,380 Oruka Therapeutics shares in Q2 2025, an estimated $75.7K.
  • Artia Global Partners first reported a position in Oruka Therapeutics in Q1 2025 and held it in 1 quarter.
  • Artia Global Partners's Oruka Therapeutics position peaked at $75.7K in Q1 2025.
  • 81 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2025.

Based on Artia Global Partners's 13F filing for Q2 2025, filed 14 Aug 2025.